179 related articles for article (PubMed ID: 12210290)
1. Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding.
Mihara K; Kondo T; Higuchi H; Takahashi H; Yoshida K; Shimizu T; Kaneko S
Am J Med Genet; 2002 Aug; 114(6):693-5. PubMed ID: 12210290
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study.
Sáiz PA; García-Portilla MP; Arango C; Morales B; Arias B; Corcoran P; Fernández JM; Alvarez V; Coto E; Bascarán MT; Bousoño M; Fañanas L; Bobes J
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):26-31. PubMed ID: 19766158
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of dopamine D2-like (D2, D3, and D4) receptors in schizophrenia.
Ohara K; Nakamura Y; Xie DW; Ishigaki T; Deng ZL; Tani K; Zhang HY; Kondo N; Liu JC; Miyasato K; Ohara K
Biol Psychiatry; 1996 Dec; 40(12):1209-17. PubMed ID: 8959285
[TBL] [Abstract][Full Text] [Related]
5. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.
Wu S; Xing Q; Gao R; Li X; Gu N; Feng G; He L
Neurosci Lett; 2005 Mar; 376(1):1-4. PubMed ID: 15694263
[TBL] [Abstract][Full Text] [Related]
6. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
[TBL] [Abstract][Full Text] [Related]
7. Association study between the -141C Ins/Del and TaqI A polymorphisms of the dopamine D2 receptor gene and alcoholism.
Ishiguro H; Arinami T; Saito T; Akazawa S; Enomoto M; Mitushio H; Fujishiro H; Tada K; Akimoto Y; Mifune H; Shioduka S; Hamaguchi H; Toru M; Shibuya H
Alcohol Clin Exp Res; 1998 Jun; 22(4):845-8. PubMed ID: 9660310
[TBL] [Abstract][Full Text] [Related]
8. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics.
Woo SI; Kim JW; Rha E; Han SH; Hahn KH; Park CS; Sohn JW
Psychiatry Clin Neurosci; 2002 Aug; 56(4):469-74. PubMed ID: 12109967
[TBL] [Abstract][Full Text] [Related]
9. [Clinical pharmacogenetics in the treatment of schizophrenia].
Saito M; Yasui-Furukori N; Kaneko S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
[TBL] [Abstract][Full Text] [Related]
10. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N
Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435
[TBL] [Abstract][Full Text] [Related]
11. Association study between antipsychotics- induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia.
Kang SG; Lee HJ; Choi JE; Park YM; Park JH; Han C; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
Neuropsychobiology; 2008; 57(1-2):49-54. PubMed ID: 18451638
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between the effectiveness of atypical antipsychotics and dopamine D3 receptor polymorphism in schizophrenia].
Szekeres G; Juhász A; Kéri S; Rimanóczy A; Szendi I; Szabó Z; Janka Z
Ideggyogy Sz; 2002 Nov; 55(11-12):377-81. PubMed ID: 12632798
[TBL] [Abstract][Full Text] [Related]
13. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response.
Reynolds GP; Yao Z; Zhang X; Sun J; Zhang Z
Eur Neuropsychopharmacol; 2005 Mar; 15(2):143-51. PubMed ID: 15695058
[TBL] [Abstract][Full Text] [Related]
15. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
[TBL] [Abstract][Full Text] [Related]
16. [Association of schizophrenia with a promoter polymorphism in the dopamine D2 receptor gene].
Peng DH; Wang GH; Cheng ZL; Zhang DX; Jiang KD
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Feb; 22(1):94-5. PubMed ID: 15696493
[TBL] [Abstract][Full Text] [Related]
17. [No association of 141C-ins/del polymorphism in the D2 dopamine receptor gene in schizophrenia].
Rohrmeier T; Putzhammer A; Sartor H; Knapp M; Albus M; Borrmann-Hassenbach M; Lichtermann D; Wildenauer D; Schwab S; Maier W; Klein HE; Eichhammer P
Psychiatr Prax; 2003 May; 30 Suppl 2():S212-5. PubMed ID: 14509080
[TBL] [Abstract][Full Text] [Related]
18. Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients.
Kondo T; Mihara K; Suzuki A; Yasui-Furukori N; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):921-6. PubMed ID: 14499308
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D3 receptor (DRD3) gene polymorphism is associated with the intensity of eye movement disturbances in schizophrenic patients and healthy subjects.
Rybakowski JK; Borkowska A; Czerski PM; Hauser J
Mol Psychiatry; 2001 Nov; 6(6):718-24. PubMed ID: 11673801
[TBL] [Abstract][Full Text] [Related]
20. The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and -141C Ins/Del polymorphisms.
Himei A; Koh J; Sakai J; Inada Y; Akabame K; Yoneda H
Psychiatry Clin Neurosci; 2002 Feb; 56(1):97-102. PubMed ID: 11929577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
